Advertisement

Topics

Inhibition of radiographic progression independent of disease activity for adalimumab in PsA

06:00 EDT 22 Jun 2017 | Healio

MADRID — Inhibition of radiographic progression was independent of disease activity for adalimumab in patients with psoriatic arthritis, according to findings presented at the EULAR Annual Congress. “There was less radiographic progression in patients treated with adalimumab compared to patients treated with placebo,” Robert Landewe, MD, from the University of Amsterdam, said. “Across all different disease activity categories with significant differences in patients with moderate and high disease activity, radiographic progression still correlated moderately well with disease activity in patients treated with placebo, but did not in patients treated with adalimumab.” He added, the findings, “support a disconnect phenomenon following adalimumab treatment.”

Original Article: Inhibition of radiographic progression independent of disease activity for adalimumab in PsA

NEXT ARTICLE

More From BioPortfolio on "Inhibition of radiographic progression independent of disease activity for adalimumab in PsA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....